You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

CLINICAL TRIALS PROFILE FOR OLANZAPINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for olanzapine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000374 ↗ Treatment for First-Episode Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 ↗ Treatment for First-Episode Schizophrenia Completed The Zucker Hillside Hospital Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 ↗ Treatment for First-Episode Schizophrenia Completed Northwell Health Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00001656 ↗ Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders Completed National Institute of Mental Health (NIMH) Phase 4 1997-06-01 The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses. Childhood psychosis is a serious disorder that may have devastating consequences. Effective treatments for the condition are under continual investigation. This study will examine the causes of and offer treatment for childhood psychosis. Participants in this study will undergo psychological tests, blood and urine tests, electroencephalogram (EEG), electrocardiogram (EKG), and magnetic resonance imaging (MRI) scans of the brain for the first 1 to 2 weeks of the study while taking their regular medications. Participants will then be tapered off their medications over 1 to 3 weeks and will continue to stay off medications for an additional 2 days to 3 weeks. During this time, participants will undergo psychiatric, neurological, and cardiac examinations as well as blood tests. After this period without medications, participants will be randomly assigned to receive either clozapine or olanzapine for 8 weeks. An EEG will be performed prior to treatment and after 6 weeks of study medication. Participants who respond well to the study drugs may continue to receive them through their own physician. Participants who do not respond to either clozapine or olanzapine or cannot tolerate their side effects will be treated individually with other drugs until optimum treatment is identified. Regular telephone updates and in person visits to NIH for repeat testing and MRIs will be conducted.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for olanzapine

Condition Name

Condition Name for olanzapine
Intervention Trials
Schizophrenia 237
Bipolar Disorder 55
Schizoaffective Disorder 54
Psychotic Disorders 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for olanzapine
Intervention Trials
Schizophrenia 254
Psychotic Disorders 90
Disease 83
Bipolar Disorder 68
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for olanzapine

Trials by Country

Trials by Country for olanzapine
Location Trials
Canada 73
China 51
Germany 43
Spain 39
India 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for olanzapine
Location Trials
New York 83
California 78
Texas 63
Ohio 57
Florida 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for olanzapine

Clinical Trial Phase

Clinical Trial Phase for olanzapine
Clinical Trial Phase Trials
Phase 4 165
Phase 3 131
Phase 2/Phase 3 10
[disabled in preview] 118
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for olanzapine
Clinical Trial Phase Trials
Completed 348
Terminated 39
Recruiting 35
[disabled in preview] 69
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for olanzapine

Sponsor Name

Sponsor Name for olanzapine
Sponsor Trials
Eli Lilly and Company 86
National Institute of Mental Health (NIMH) 33
Pfizer 17
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for olanzapine
Sponsor Trials
Other 475
Industry 276
NIH 53
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.